Clinical trial
Phase-II Study of SU011248 (Sunitinib)in Male Patients With Relapsed or…
NCT00371553 · British Columbia Cancer Agency, Other · Completed
Key facts
| NCT number | NCT00371553 |
|---|---|
| Title | Phase-II Study of SU011248 (Sunitinib)in Male Patients With Relapsed or Cisplatin-Refractory Germ Cell Cancer |
| Official title | Prospective Open-Labeled Non Randomised Phase-II Study of SU011248 (Sunitinib) in Male Patients With Relapsed or Cisplatin-Refractory Germ Cell Cancer - A CUOG / GTCSG Cooperative Phase II Study - |
| Lead sponsor | British Columbia Cancer Agency, Other |
| Collaborators | Canadian Urologic Oncology Group NCIC Testis Group German Testicular Cancer Study Group |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Relapsed or Cisplatin-Refractory Germ Cell Cancer |
| Intervention type | Drug |
| Interventions | SU011248 (Sunitinib) |
| Enrollment | 33 |
| Start date | Nov 1, 2006 |
| Primary completion | Jun 1, 2009 |
| Completion | Jun 1, 2009 |
| First posted | Sep 4, 2006 |
| Last update posted | Jul 8, 2009 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: